NESS ZIONA, Israel, Aug. 15, 2018 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (NASDAQ: SLGL) (`Sol-Gel` or the `Company`), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced it has entered into a collaborative agreement with Perrigo Israel, an affiliate of Perrigo Company plc (`Perrigo`) (NYSE; TASE: PRGO), for the development, manufacturing and commercialization of a generic product candidate. Under the terms of the agreement, Perrigo will conduct the regulatory, scientific, clinical and technical activities necessary to develop the generic product...
|
